GEA007.1 has the potential to be a ‘next generation’ interferon for the treatment of HCV infection. It may be positioned as 1st-line therapy with equivalent activity but lower toxicity, and/or positioned for use in non-responders or relapsing patients infected with HCV genotype 1 and genotype 3.
GEA007.1 is a novel, natural, highly potent antiviral IFN alpha variant that has demonstrated stronger anti-HCV replication activity in vitro in the replicon assay than IFN alpha 2a (Roferon®) and IFN alpha 2b (Intron A®). Importantly, GEA007.1 has demonstrated better efficacy in HCV-genotype 1b clearance from human hepatocytes. GEA007.1 anti-HCV activity profile is also associated with improved global antiviral and anti-proliferative activity, sustained by a stronger activation of the classical IFN type 1 receptor signaling pathway in human target cells, compared to standard IFN alpha 2. Preliminary safety pharmacology studies conducted in rhesus monkeys have demonstrated a profile similar to IFN alpha 2. Therefore GEA007.1 has the potential to provide higher efficacy and/or wider therapeutic index than IFN’s currently used in clinical treatment of Hepatitis C. In particular, GEA007.1 may have significant advantage in addressing viral resistance to IFN alpha 2 therapies in Hepatitis C.
GEA007.1 is a naturally occurring IFN variant, which incorporates the amino acid substitution G45R in the human IFN alpha 17 protein. This provides a novel positive charge in the receptor binding site together with a change in 3-D structure of the protein. The gene coding for GEA007.1 is present in all major human populations (Pacific, Iberian, Italian, Mexican, African, Caucasian, Chinese, Indo-Pakistan, Middle-Eastern, Japanese).

GEA007.1 PDF

GEA009.2 has the potential to be a ‘first in class’ cancer drug. It activates a novel pathway in human immune cells (with no activation of the classical IFN type 1 transduction pathway). It thus provides a profile characterized by powerful immunomodulating properties dissociated from weak anti-proliferative and antiviral activity. In animal models it exhibits higher efficacy / better survival rates and lower toxicity than current IFN alpha 2 treatments. GEA009.2 has the potential to substantially increase patient survival and comfort compared to current IFN therapy and to extend IFN therapy to a broader range of cancers and innovative immunotherapy treatments.
GEA009.2 is a novel, natural human genetic variant of IFN alpha 21 discovered using GenOdyssee’s proprietary technology. It incorporates a single amino acid substitution, K179E, in human IFN alpha 21 protein. This provides a positive-to-negative charge inversion and a change in 3-dimensional structure of the protein within that part of the protein involved in receptor binding. The gene variant that codes for GEA009.2 is present in the following populations: Mexican, Chinese, South American, Japanese.

GEA009.2 PDF

GOEPO (Erythropoietin, 1 variant):

GO-EPO is a naturally-improved erythropoietin alpha (EPO) variant that has the potential to increase erythroid and erythroid progenitor cell re-constitution in anemic patients, compared to wild-type (WT) EPO. Its improved potency compared to currently marketed EPO’s may allow it to be used at lower doses in several anaemia indications. GO-EPO is the first natural and therapeutically active EPO alpha molecule listed in the USPTO database since Amgen’s. Its natural nature combined with improved potency makes it a unique and low risk opportunity to address the largest biotech market of the industry. This positions GO-EPO as a candidate next-generation EPO for 1st-line therapy in anaemia indications.


GO-EPO PDF